Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3029% below fair value
$61.35−1.58 (-2.51%)
Close on Nov 17, 2026Market cap $125.40BP/E 13.6Yield 4.06%
Bristol Myers Squibb ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
No ebitda figures for Bristol Myers Squibb
Bristol Myers Squibb has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?